Bovine Mastitis Market Size, Share, Growth and Analysis 2034
Bovine Mastitis Market Growth, Size, Trends Analysis- By Product, By Route of Administration, By Therapy, By Type, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25230 | Pages: 1 - 256 | Formats*: |
| Category : Healthcare | |||
Bovine Mastitis Market Introduction and Overview
According to SPER Market Research, the Global Bovine Mastitis Market is estimated to reach USD 4.05 billion by 2034 with a CAGR of 8.32%.
The report includes an in-depth analysis of the Global Bovine Mastitis Market, including market size and trends, product mix, Applications, and supplier analysis. The Bovine Mastitis Market was valued at USD 1.82 billion in 2024 and is expected to grow at a CAGR of 8.32% from 2025 to 2034. The primary driver of the rapid expansion of the bovine mastitis prevention and treatment industry is the rising incidence of udder infections in dairy cattle. The growing demand for high-quality milk and the expansion of dairy production have highlighted the importance of effectively managing mastitis. Growing knowledge of the disease's effects on the economy and animal welfare among farmers, veterinarians, and other stakeholders is also anticipated to be a major factor in the expansion of the sector and promote the use of cutting-edge diagnostics, vaccines, and treatment options.
By Route Of Administration Insights:
Because it effectively targets the infection within the udder, the intra-mammary sector dominated the market in 2024. By delivering therapeutic drugs directly into the afflicted mammary gland, the intra-mammary method guarantees high concentrations of the drug at the infection site. Treatment results are improved by this focused strategy, especially for bacterial infections like Escherichia coli and Staphylococcus aureus. An important consideration for dairy farmers is that intra-mammary therapies, as opposed to systemic injection, reduce drug exposure to the rest of the animal's body, minimising adverse effects and milk withdrawal times.
By Type Insights:
In 2024, clinical mastitis had the biggest market share. Clinical mastitis is an inflammatory response to disease that causes milk to clearly deviate from normal (for example, colour or fibrin clots). As the inflammation progresses, the udder may also exhibit changes like swelling, heat production, discomfort, and redness. Products like supportive therapy, anti-inflammatory medications, and antibiotics are often used to treat clinical mastitis. As a result, there is a strong need for therapies designed especially for this illness.
Regional Insights:
Due to the expanding number of cattle and the need to satisfy customer demands for sustainable animal protein sources, the North American bovine mastitis market had the greatest revenue share in 2024. Milk production and quality are significantly impacted by mastitis. Preventing or effectively controlling this disease is essential to sustaining production, meeting the world's increasing need for animal protein, and meeting environmental goals.
Market Competitive Landscape:
The Bovine Mastitis Market is dominated by established players such as Boehringer, Ceva, Elanco, Forte Healthcare Ltd, Heilsaa, HIPRA, Immucell Corporation, Merck, Virbac, and Zoetis, as well as a number of small and medium-sized companies. because of their robust R&D capacities, wide range of products, and international distribution systems. These businesses continuously make investments in innovation, developing cutting-edge products like vaccinations, preventive treatments, and intramammary antibiotics to meet the changing demands of dairy farmers.
Recent Developments:
In certain European markets, Zoetis introduced Vetscan Masti gramme in August 2023. This fast on-farm mastitis test can detect Gram-positive mastitis in just eight hours using a standard flow dipstick test, enabling findings before the next milking.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Route of Administration, By Therapy, By Type, By End-User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Boehringer, Ceva, Elanco, Forte Healthcare Ltd, Heilsaa, HIPRA, Immucell Corporation, Merck, Virbac, Zoetis. |
- Global Bovine Mastitis Market Size (FY 2021-FY 2034)
- Overview of Global Bovine Mastitis Market
- Segmentation of Global Bovine Mastitis Market by Product (Pharmaceuticals, Antibiotics, Vaccines, Diagnostics, Others)
- Segmentation of Global Bovine Mastitis Market by Route of Administration (Intra-Mammary, Systemic)
- Segmentation of Global Bovine Mastitis Market by Therapy (Dry Period, Lactating Period)
- Segmentation of Global Bovine Mastitis Market by Type (Clinical Mastitis, Sub-Clinical Mastitis)
- Segmentation of Global Bovine Mastitis Market by End-User (Veterinary Hospitals/Clinics, Others)
- Statistical Snap of Global Bovine Mastitis Market
- Expansion Analysis of Global Bovine Mastitis Market
- Problems and Obstacles in Global Bovine Mastitis Market
- Competitive Landscape in the Global Bovine Mastitis Market
- Details on Current Investment in Global Bovine Mastitis Market
- Competitive Analysis of Global Bovine Mastitis Market
- Prominent Players in the Global Bovine Mastitis Market
- SWOT Analysis of Global Bovine Mastitis Market
- Global Bovine Mastitis Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Bovine Mastitis Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Bovine Mastitis Market
7. Global Bovine Mastitis Market, By Product (USD Million) 2021-2034
- 7.1. Pharmaceuticals
- 7.2. Diagnostics
- 7.3. Antibiotics
- 7.4. Vaccines
- 7.5. Others
8. Global Bovine Mastitis Market, By Route of Administration ((USD Million) 2021-2034
- 8.1. Intra-Mammary
- 8.2. Systemic
9. Global Bovine Mastitis Market, By Therapy (USD Million) 2021-2034
- 9.1. Dry Period
- 9.2. Lactating Period
10. Global Bovine Mastitis Market, By Type (USD Million) 2021-2034
- 10.1. Clinical Mastitis
- 10.2. Sub-Clinical Mastitis
11. Global Bovine Mastitis Market, By End-User (USD Million) 2021-2034
- 11.1. Veterinary Hospitals/Clinics
- 11.2. Others
12. Global Bovine Mastitis Market, (USD Million) 2021-2034
- 12.1. Global Bovine Mastitis Market Size and Market Share
13. Global Bovine Mastitis Market, By Region, (USD Million) 2021-2034
- 13.1. Asia-Pacific
- 13.1.1. Australia
- 13.1.2. China
- 13.1.3. India
- 13.1.4. Japan
- 13.1.5. South Korea
- 13.1.6. Rest of Asia-Pacific
- 13.2. Europe
- 13.2.1. France
- 13.2.2. Germany
- 13.2.3. Italy
- 13.2.4. Spain
- 13.2.5. United Kingdom
- 13.2.6. Rest of Europe
- 13.3. Middle East and Africa
- 13.3.1. Kingdom of Saudi Arabia
- 13.3.2. United Arab Emirates
- 13.3.3. Qatar
- 13.3.4. South Africa
- 13.3.5. Egypt
- 13.3.6. Morocco
- 13.3.7. Nigeria
- 13.3.8. Rest of Middle-East and Africa
- 13.4. North America
- 13.4.1. Canada
- 13.4.2. Mexico
- 13.4.3. United States
- 13.5. Latin America
- 13.5.1. Argentina
- 13.5.2. Brazil
- 13.5.3. Rest of Latin America
14. Company Profile
- 14.1. Boehringer
- 14.1.1. Company details
- 14.1.2. Financial outlook
- 14.1.3. Product summary
- 14.1.4. Recent developments
- 14.2. Ceva
- 14.2.1. Company details
- 14.2.2. Financial outlook
- 14.2.3. Product summary
- 14.2.4. Recent developments
- 14.3. Elanco
- 14.3.1. Company details
- 14.3.2. Financial outlook
- 14.3.3. Product summary
- 14.3.4. Recent developments
- 14.4. Forte Healthcare Ltd
- 14.4.1. Company details
- 14.4.2. Financial outlook
- 14.4.3. Product summary
- 14.4.4. Recent developments
- 14.5. Heilsaa
- 14.5.1. Company details
- 14.5.2. Financial outlook
- 14.5.3. Product summary
- 14.5.4. Recent developments
- 14.6. HIPRA
- 14.6.1. Company details
- 14.6.2. Financial outlook
- 14.6.3. Product summary
- 14.6.4. Recent developments
- 14.7. Immucell Corporation
- 14.7.1. Company details
- 14.7.2. Financial outlook
- 14.7.3. Product summary
- 14.7.4. Recent developments
- 14.8. Merck
- 14.8.1. Company details
- 14.8.2. Financial outlook
- 14.8.3. Product summary
- 14.8.4. Recent developments
- 14.9. Zoetis
- 14.9.1. Company details
- 14.9.2. Financial outlook
- 14.9.3. Product summary
- 14.9.4. Recent developments
- 14.10. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Bovine Mastitis Market is projected to reach USD 4.05 billion by 2034, growing at a CAGR of of 8.32% during the forecast period.
Bovine Mastitis Market grew in Market size from 2025. The Market is expected to reach USD 4.05 billion by 2034, at a CAGR of 8.32% during the forecast period.
Bovine Mastitis Market CAGR of 8.32% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Bovine Mastitis Market size is USD 4.05 billion from 2025 to 2034.
Bovine Mastitis Market is covered By Product, By Route of Administration, By Therapy, By Type, By End-User
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Bovine Mastitis Market.
Boehringer, Ceva, Elanco, Forte Healthcare Ltd, Heilsaa, HIPRA, Immucell Corporation, Merck, Virbac, Zoetis.
The report includes an in-depth analysis of the Global Bovine Mastitis Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
